Glenmark Pharma

Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated December 11, 2025, titled "Glenmark Pharmaceuticals Inc., USA to launch Leucovorin Calcium for...

11 Dec, 2025 | 11:15am • Source: NSE

Glenmark Pharmaceuticals Inc., USA to launch Leucovorin Calcium for Injection USP, 350 mg/ vial Single - Dose Vial

11 Dec, 2025 | 08:44am • Source: BSE

Update on the Company''s Chhatrapati Sambhajinagar (Aurangabad) Facility

01 Dec, 2025 | 08:56am • Source: BSE

Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 27, 2025, titled "Glenmark Pharmaceuticals receives Establishment Inspection Report (EIR) from U.S....

27 Nov, 2025 | 10:19am • Source: NSE

Update on the Company''s Monroe, North Carolina (USA) Facility

27 Nov, 2025 | 10:15am • Source: BSE

Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 25, 2025, titled "Glenmark Pharmaceuticals Announces Launch of Nebzmart® GFB Smartules® and...

25 Nov, 2025 | 09:21am • Source: NSE

Glenmark Pharmaceuticals Announces Launch of Nebzmart GFB Smartules and Glenmark Airz FB Smartules, World''s First Nebulized Triple Therapy for COPD

25 Nov, 2025 | 09:00am • Source: BSE

Transcript of Earnings Call is attached

19 Nov, 2025 | 05:17pm • Source: BSE

Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 18, 2025, titled "Cosmo and Glenmark Announce Market Authorization of Winlevi® (clascoterone)...

18 Nov, 2025 | 03:02pm • Source: NSE

Pursuant to the Regulation 30 and 46 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we...

17 Nov, 2025 | 01:01pm • Source: BSE

Please find attached details of Analyst / Institutional Investor meeting.

14 Nov, 2025 | 06:19pm • Source: BSE

Investor Presentation - Q2 FY 25-26

14 Nov, 2025 | 06:12pm • Source: BSE

Please find attached Press Release and Management Discussion & Analysis for the second quarter ended September 30, 2025

14 Nov, 2025 | 06:04pm • Source: BSE

Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the Board at its...

14 Nov, 2025 | 05:51pm • Source: BSE

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

14 Nov, 2025 | 03:34pm • Source: BSE

Glenmark Secures China Approval for RYALTRIS, Reinforcing Respiratory Innovation Leadership

10 Nov, 2025 | 03:30pm • Source: BSE

Enclosed please find herewith the details of Earnings Call slated for Monday, November 17, 2025 at 8:30 a.m. - 9:30 a.m. (IST), for your information...

06 Nov, 2025 | 12:51pm • Source: BSE

Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 04, 2025, titled "Glenmark Pharmaceuticals Inc., USA to launch 8.4% Sodium Bicarbonate...

04 Nov, 2025 | 10:45am • Source:

Glenmark Pharmaceuticals Inc., USA launch 8.4% Sodium Bicarbonate Injection USP, 50 mEq/ 50mL (1 mEq/ mL) Single - Dose Vial

04 Nov, 2025 | 08:59am • Source: BSE

The Company has intimated regarding the closure of trading window from September 30, 2025 to November 16, 2025 (both days inclusive) for the purpose of...

03 Nov, 2025 | 05:38pm • Source: BSE